Bank of New York Mellon
ACUR

Bank of New York Mellon’s Acura Pharmaceuticals ACUR Stock Holding History

Bank of New York Mellon’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,158
Closed -$11K – 4422
2015
Q2 		$11K Buy
+2,158
New +$8.96K ﹤0.01% 4256

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Bank of New York Mellon's ACUR Position: Q3 2015 in Review

Bank of New York Mellon sold out of Acura Pharmaceuticals (ACUR) in Q3 2015, closing a stake of 2,158 shares — an estimated $11K sold.

Bank of New York Mellon first reported a position in ACUR in Q2 2015 and held it in 1 quarter. The position peaked at $11K in Q2 2015. 22 funds tracked by Wall St. Rank hold ACUR as of Q3 2015.

  • Bank of New York Mellon reported no remaining Acura Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Bank of New York Mellon sold 2,158 Acura Pharmaceuticals shares in Q3 2015, an estimated $11K.
  • Bank of New York Mellon first reported a position in Acura Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Bank of New York Mellon's Acura Pharmaceuticals position peaked at $11K in Q2 2015.
  • 22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q3 2015.

Based on Bank of New York Mellon's 13F filing for Q3 2015, filed 10 Nov 2015.